Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | FADS1 | O60427 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6341269 | 0.87 | RECQL (0.60) | ALOX15PARP1RECQLFADS1POLB | |
| SCHEMBL28751447 | 0.86 | RECQL (0.56) | ALOX15RECQLPOLBMAPTALDH1A1 | |
| SCHEMBL9383428 | 0.84 | MAPT (0.54) | RECQLPOLBMAPTALDH1A1GAA | |
| SCHEMBL5740187 | 0.82 | MAPT (0.65) | ALOX15PARP1RECQLFADS1POLB | |
| SCHEMBL29963936 | 0.82 | MAPT (0.65) | ALOX15PARP1RECQLFADS1POLB | |
| SCHEMBL1877051 | 0.82 | MAPT (0.64) | POLBMAPTALDH1A1GAAKMT2A | |
| SCHEMBL29980197 | 0.82 | MAPT (0.64) | POLBMAPTALDH1A1GAAKMT2A | |
| SCHEMBL1757757 | 0.81 | MAPT (0.69) | ALOX15PARP1RECQLFADS1POLB | |
| SCHEMBL3025938 | 0.78 | PARP1 (0.53) | ALOX15PARP1ALDH1A1 | |
| SCHEMBL5484462 | 0.78 | CES2 (0.53) | MAPTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | ALOX15 4082/4885PARP1 2042/4885RECQL 1716/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | ALOX15 4082/4885PARP1 2042/4885RECQL 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.